Crohn's disease Trials in Clearwater, United States
Conditions / Crohn's disease / Clearwater, United States
Clinical trials for Crohn's disease investigate a range of treatment strategies and patient populations.
48 total trials for this combination
Showing top 10 of 48 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT03926130 | A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | COMPLETED | PHASE3 |
| NCT03283085 | A Safety Extension Study of Ontamalimab in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease (AIDA) | COMPLETED | PHASE3 |
| NCT06430801 | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) | RECRUITING | — |
| NCT03104413 | A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment | COMPLETED | PHASE3 |
| NCT03599622 | An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease | TERMINATED | PHASE2 |
| NCT04232553 | A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | COMPLETED | PHASE3 |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | COMPLETED | PHASE3 |
| NCT04173273 | A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease | TERMINATED | PHASE3 |
| NCT03105128 | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 |